528 related articles for article (PubMed ID: 33048929)
1. Health outcomes and cost-effectiveness of diversion programs for low-level drug offenders: A model-based analysis.
Bernard CL; Rao IJ; Robison KK; Brandeau ML
PLoS Med; 2020 Oct; 17(10):e1003239. PubMed ID: 33048929
[TBL] [Abstract][Full Text] [Related]
2. Estimation of the cost-effectiveness of HIV prevention portfolios for people who inject drugs in the United States: A model-based analysis.
Bernard CL; Owens DK; Goldhaber-Fiebert JD; Brandeau ML
PLoS Med; 2017 May; 14(5):e1002312. PubMed ID: 28542184
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs.
Barbosa C; Fraser H; Hoerger TJ; Leib A; Havens JR; Young A; Kral A; Page K; Evans J; Zibbell J; Hariri S; Vellozzi C; Nerlander L; Ward JW; Vickerman P
Addiction; 2019 Dec; 114(12):2267-2278. PubMed ID: 31307116
[TBL] [Abstract][Full Text] [Related]
4. Estimating the cost-effectiveness of needle-syringe programs in Australia.
Kwon JA; Anderson J; Kerr CC; Thein HH; Zhang L; Iversen J; Dore GJ; Kaldor JM; Law MG; Maher L; Wilson DP
AIDS; 2012 Nov; 26(17):2201-10. PubMed ID: 22914579
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO-HCV trial.
Lim AG; Aas CF; Çağlar ES; Vold JH; Fadnes LT; Vickerman P; Johansson KA
Addiction; 2023 Dec; 118(12):2424-2439. PubMed ID: 37515462
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness and cost-effectiveness of diversion and aftercare programmes for offenders using class A drugs: a systematic review and economic evaluation.
Hayhurst KP; Leitner M; Davies L; Flentje R; Millar T; Jones A; King C; Donmall M; Farrell M; Fazel S; Harris R; Hickman M; Lennox C; Mayet S; Senior J; Shaw J
Health Technol Assess; 2015 Jan; 19(6):1-168, vii-viii. PubMed ID: 25619533
[TBL] [Abstract][Full Text] [Related]
7. Associations of criminal justice and substance use treatment involvement with HIV/HCV testing and the HIV treatment cascade among people who use drugs in Oakland, California.
Lambdin BH; Kral AH; Comfort M; Lopez AM; Lorvick J
Addict Sci Clin Pract; 2017 Jun; 12(1):13. PubMed ID: 28610602
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of the HepCATT intervention in specialist drug clinics to improve case-finding and engagement with HCV treatment for people who inject drugs in England.
Ward Z; Reynolds R; Campbell L; Martin NK; Harrison G; Irving W; Hickman M; Vickerman P
Addiction; 2020 Aug; 115(8):1509-1521. PubMed ID: 31984606
[TBL] [Abstract][Full Text] [Related]
9. Costs and impact on HIV transmission of a switch from a criminalisation to a public health approach to injecting drug use in eastern Europe and central Asia: a modelling analysis.
Ward Z; Stone J; Bishop C; Ivakin V; Eritsyan K; Deryabina A; Low A; Cepeda J; Kelly SL; Heimer R; Cook R; Altice FL; Litz T; Terlikbayeva A; El-Bassel N; Havarkov D; Fisenka A; Boshnakova A; Klepikov A; Saliuk T; Deshko T; Vickerman P
Lancet HIV; 2022 Jan; 9(1):e42-e53. PubMed ID: 34895484
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
[TBL] [Abstract][Full Text] [Related]
11. Detachable low dead space syringes for the prevention of hepatitis C among people who inject drugs in Bristol, UK: an economic evaluation.
Hancock E; Ward Z; Ayres R; Neale J; Hussey D; Kesten JM; Hickman M; Vickerman P
Addiction; 2020 Apr; 115(4):702-713. PubMed ID: 31633849
[TBL] [Abstract][Full Text] [Related]
12. Modelling the impact and cost-effectiveness of non-governmental organizations on HIV and HCV transmission among people who inject drugs in Ukraine.
Stone J; Trickey A; Walker JG; Bivegete S; Semchuk N; Sazonova Y; Varetska O; Altice FL; Saliuk T; Vickerman P
J Int AIDS Soc; 2023 Apr; 26(4):e26073. PubMed ID: 37012669
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids.
Barocas JA; Morgan JR; Fiellin DA; Schackman BR; Eftekhari Yazdi G; Stein MD; Freedberg KA; Linas BP
Int J Drug Policy; 2019 Oct; 72():160-168. PubMed ID: 31085063
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the cost-effectiveness of existing needle and syringe programmes in preventing hepatitis C transmission in people who inject drugs.
Sweeney S; Ward Z; Platt L; Guinness L; Hickman M; Hope V; Maher L; Iversen J; Hutchinson SJ; Smith J; Ayres R; Hainey I; Vickerman P
Addiction; 2019 Mar; 114(3):560-570. PubMed ID: 30674091
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of Direct Antiviral Agents for Hepatitis C Virus Infection and a Combined Intervention of Syringe Access and Medication-assisted Therapy for Opioid Use Disorders in an Injection Drug Use Population.
Stevens ER; Nucifora KA; Hagan H; Jordan AE; Uyei J; Khan B; Dombrowski K; des Jarlais D; Braithwaite RS
Clin Infect Dis; 2020 Jun; 70(12):2652-2662. PubMed ID: 31400755
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree.
Ijioma SC; Pontinha VM; Holdford DA; Carroll NV
J Manag Care Spec Pharm; 2021 Feb; 27(2):137-146. PubMed ID: 33506729
[No Abstract] [Full Text] [Related]
17. Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs.
Schackman BR; Leff JA; Barter DM; DiLorenzo MA; Feaster DJ; Metsch LR; Freedberg KA; Linas BP
Addiction; 2015 Jan; 110(1):129-43. PubMed ID: 25291977
[TBL] [Abstract][Full Text] [Related]
18. Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model.
Scott N; McBryde ES; Thompson A; Doyle JS; Hellard ME
Gut; 2017 Aug; 66(8):1507-1515. PubMed ID: 27196586
[TBL] [Abstract][Full Text] [Related]
19. Ending the HIV Epidemic Among Persons Who Inject Drugs: A Cost-Effectiveness Analysis in Six US Cities.
Krebs E; Zang X; Enns B; Min JE; Behrends CN; Del Rio C; Dombrowski JC; Feaster DJ; Gebo KA; Marshall BDL; Mehta SH; Metsch LR; Pandya A; Schackman BR; Strathdee SA; Nosyk B;
J Infect Dis; 2020 Sep; 222(Suppl 5):S301-S311. PubMed ID: 32877548
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia.
Scott N; Iser DM; Thompson AJ; Doyle JS; Hellard ME
J Gastroenterol Hepatol; 2016 Apr; 31(4):872-82. PubMed ID: 26514998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
